Does Rallies show 13F holders for EW?

Yes. Rallies tracks hedge fund and 13F ownership data for EW, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EW research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EW. It does not provide personalized investment advice.

EW (Edwards Lifesciences) Stock Analysis - Hedge Fund Holdings

Edwards Lifesciences (EW) is a publicly traded Healthcare sector company. As of May 20, 2026, EW trades at $82.46 with a market cap of $47.44B and a P/E ratio of 43.66. EW moved +0.84% today. Year to date, EW is -1.43%; over the trailing twelve months it is +6.60%. Its 52-week range spans $64.01 to $87.89. Analyst consensus is strong buy with an average price target of $97.80. Rallies surfaces EW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EW stock?

Hedge funds tracked by Rallies that own EW include Orbimed Advisors, Viking Global, Soros Fund, Pinebridge Investments, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Edwards Lifesciences.

EW Key Metrics

Key financial metrics for EW
Metric	Value
Price	$82.46
Market Cap	$47.44B
P/E Ratio	43.66
EPS	$1.89
Dividend Yield	0.00%
52-Week High	$87.89
52-Week Low	$64.01
Volume	3.24M
Avg Volume	0
Revenue (TTM)	$6.30B
Net Income	$1.09B
Gross Margin	77.87%

Top Hedge Funds Holding EW

Orbimed Advisors holds 1.23M shares of EW, changed -33.22% as of Mar 31, 2026.
Viking Global holds 1.10M shares of EW, changed -64.24% as of Mar 31, 2026.
Soros Fund holds 250.00K shares of EW, changed -16.67% as of Dec 31, 2024.
Pinebridge Investments holds 195.71K shares of EW, changed +21.14% as of Sep 30, 2025.
Bridgewater Associates holds 171.92K shares of EW, changed +123.97% as of Mar 31, 2026.

Latest EW News

Edwards Lifesciences jumps on Q1 beat and higher 2026 sales, EPS outlook — Apr 26, 2026
Edwards Lifesciences jumps as Q1 beat drives higher 2026 sales outlook — Apr 25, 2026
Edwards Lifesciences Q1 Sales Up 16.7%, Lifts 2026 Guidance to 9–11% Growth — Apr 24, 2026
Edwards Lifesciences jumps after Q1 beat and higher 2026 sales outlook — Apr 24, 2026
Edwards Lifesciences Lifts 2026 Guidance to 9%–11% After 11% TAVR Growth — Apr 24, 2026

Recent EW Insider Trades

Lippis Daniel J. sold 620 (~$50.31K) on May 18, 2026.
BOBO DONALD E JR sold 9.97K (~$818.11K) on May 15, 2026.
BOBO DONALD E JR sold 8.00K (~$654.57K) on May 15, 2026.

EW Analyst Consensus

17 analysts cover EW: 0 strong buy, 14 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $97.80.

Common questions about EW

Who owns EW stock?: Hedge funds tracked by Rallies that own EW include Orbimed Advisors, Viking Global, Soros Fund, Pinebridge Investments, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Edwards Lifesciences.
Does Rallies show 13F holders for EW?: Yes. Rallies tracks hedge fund and 13F ownership data for EW, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EW research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EW. It does not provide personalized investment advice.